Unique Offerings Accelerate Production of CAR-TCR Therapies

From discovery to BLA, accelerate your journey from research to market.

WuXi Advanced Therapies has a proven track record in assisting cell therapy developers go from IND to BLA. We've accelerated production globally, with 40+ INDs/BLAs approved, 3,000+ GMP lots manufactured, and testing for 27+ commercial release programs.

Please share your contact information. We'll email you links to the downloads listed below.

Submit your details

Gain access to the following downloads

XOFLX™ Stable Technology: A Simplified High-Yielding LVV Manufacturing System that Lowers Costs & Improves Process Consistency

Presentation

This download was presented by Dr. Qian Liu, at the CAR-TCR Summit in London on February 28th, 2024, in London. Her presentation describes the innovative XOFLX™ (pronounced So-flex) stable technology which delivers large quantities of high-quality lentiviral vectors (LVV) with demonstrated safety and efficacy.

XOFLX™ Lenti Platform: Stable Lentiviral Vector Production Cell Lines Yield LVV Titres Comparable to the Four-Plasmid Process

Poster

This poster illustrates how XOFLX™ packaging and producer cell lines reduce/ eliminate plasmid transfection dependency, reducing manufacturing cost and process variability.

Please complete the form below to receive the downloads listed via email

"*" indicates required fields

First Name*

Last Name*

Company*

Title*

Email*

Mailing List

Please add me to your mailing list

In addition to sending the downloads, please contact me about the following*

Select all that apply

Evaluating XOFLX™ Stable Technology

Custom Discovery Services

Analytical Testing Service
(Safety, Efficacy, Stability, Viral Clearance, etc.)

Analytical Method Development

Process Development

IND Enabling Studies

Clinical Manufacturing

Commercial Manufacturing

Name

This field is for validation purposes and should be left unchanged.